FibroBiologics, Inc. (NASDAQ: FBLG) has executed a 1‑for‑20 reverse stock split, reducing the number of outstanding shares from 70,256,883 to 3,512,845. The split became effective at 12:01 a.m. Eastern Time on March 30, 2026, and trading on a split‑adjusted basis began the same day. The action raises the per‑share price and is intended to bring the company back into compliance with Nasdaq’s minimum bid‑price requirement of $1.00 per share.
The reverse split follows a series of Nasdaq compliance challenges. In July 2025, FibroBiologics received a delisting notice for failing to meet the minimum bid price. A Nasdaq Hearings Panel granted an extension in February 2026, but the company also faced a deficiency in the minimum market value of listed securities, which is $35 million. The split is a strategic move to address both deficiencies and preserve the company’s public market access while it seeks additional capital.
Shareholders approved the reverse split at a special meeting on February 20, 2026. Fractional shares resulting from the consolidation will be rounded up to the nearest whole share. Equity incentive plans, stock options, and warrants will be adjusted proportionally to reflect the new share count, ensuring that ownership percentages remain unchanged aside from rounding.
FibroBiologics reports zero revenue and a net loss of $18.6 million for the year ended December 31, 2025, compared with a $11.2 million loss in the prior year. Cash and cash equivalents stood at $4.9 million, and the company has a “WEAK” financial health score from InvestingPro, reflecting high cash burn and negative free cash flow. The firm has raised capital through direct offerings and has repaid outstanding debt, but it remains heavily reliant on research and development funding.
The company’s clinical pipeline is its primary growth engine. FibroBiologics holds more than 270 patents and is advancing a Phase 1/2 trial for a diabetic foot ulcer therapy (CYWC628) and has filed an Investigational New Drug application for a psoriasis therapy (CYPS317). Despite the lack of commercial sales, the pipeline positions the company for future revenue opportunities.
Management views the reverse split as a necessary step to regain Nasdaq compliance and maintain investor confidence. The board emphasized that while the split addresses the bid‑price requirement, there is no guarantee that the company will secure a further extension or fully meet all listing standards. The action is intended to provide a window for the company to raise additional capital and continue its clinical development.
The reverse split does not alter the company’s total market value. Ownership percentages remain effectively unchanged, aside from the rounding of fractional shares. Equity incentive plans will be adjusted proportionally, ensuring that existing shareholders retain their relative stakes in the company.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.